State of Health Episode 14: Huntington’s Disease and Patient Advocacy with Seth Rotberg

Seth Rotberg joins the podcast to talk through the in’s and out’s of patient advocacy, the patient’s role in drug development, and how patients can work with regulators to make sure the best possible medications reach approval. Since Gunnar considers himself a patient advocate, too, they are able to talk about their frustrations with the...
Continue reading...

State of Health Episode 11: Three Questions with Alaskan Governor Mike Dunleavy

In this Three Questions episode where the role of the interviewer flips halfway through the show, Gunnar and Alaska Governor, Mike Dunleavy, talk about Alaska’s early success with the state’s vaccination campaign, the state’s integrated health system and how Alaska’s reliance on telehealth could be a playbook for other states as they look to normalize...
Continue reading...

State of Health Episode 10: Drug Access in Canada with Chris MacLeod

Chris MacLeod is a Canadian living with cystic fibrosis and practicing attorney, who has been a fierce advocate for patients who need access to life-sustaining medications or treatments. He founded the not-for-profit organization Canadian Cystic Fibrosis Treatment Society to assist in carrying out this work. He also recently released a book entitled, “Beating the Odds:...
Continue reading...

State of Health Episode 9: Turning Hope into Action with Dr. David Fajgenbaum and the Castleman Disease Collaborative Network

Dr. David Fajgenbaum joins Gunnar on the podcast to talk about his New York Times Bestselling book, “Chasing My Cure: A Doctor’s Race to Turn Hope Into Action” and his journey from division 1 college football quarterback and medical student to a rare disease patient up against the clock to find a treatment for his...
Continue reading...

State of Health Episode 8: Drug Pricing, Valuing Innovation and No Patient Left Behind with Peter Kolchinsky

Biotechnology investor, Peter Kolchinsky, joins the State of Health to talk with Gunnar about drug pricing. The conversation covers the long term view that when drugs go generic without undue delay, the value they provide to society is far greater than the short-run value that cost effectiveness analyses often show, which Peter details in his...
Continue reading...